Home/Filings/4/0001181431-12-038056
4//SEC Filing

DeWitt Todd M 4

Accession 0001181431-12-038056

CIK 0001002811other

Filed

Jun 25, 8:00 PM ET

Accepted

Jun 26, 6:52 PM ET

Size

16.1 KB

Accession

0001181431-12-038056

Insider Transaction Report

Form 4
Period: 2012-06-22
DeWitt Todd M
VP of Biomaterials
Transactions
  • Disposition to Issuer

    Stock Appreciation Right

    2012-06-22$12.86/sh10,000$128,6000 total
    Exercise: $25.64Exp: 2018-09-20Common Stock (10,000 underlying)
  • Disposition to Issuer

    Employee Stock Option (right to buy)

    2012-06-22$4.14/sh14,000$57,9600 total
    Exercise: $34.36Exp: 2014-06-28Common Stock (14,000 underlying)
  • Disposition to Issuer

    Employee Stock Option (right to buy)

    2012-06-22$9.52/sh10,600$100,9120 total
    Exercise: $28.98Exp: 2020-09-20Common Stock (10,600 underlying)
  • Disposition to Issuer

    Employee Stock Option (right to buy)

    2012-06-22$6.22/sh7,000$43,5400 total
    Exercise: $32.28Exp: 2018-09-22Common Stock (7,000 underlying)
  • Disposition to Issuer

    Employee Stock Option (right to buy)

    2012-06-22$10.48/sh7,000$73,3600 total
    Exercise: $28.02Exp: 2017-10-23Common Stock (7,000 underlying)
  • Disposition to Issuer

    Employee Stock Option (right to buy)

    2012-06-22$10.02/sh10,000$100,2000 total
    Exercise: $28.48Exp: 2019-09-22Common Stock (10,000 underlying)
Footnotes (2)
  • [F1]This stock appreciation right was cancelled pursuant to the merger contemplated by the Agreement and Plan of Merger, dated as of May 2, 2012 (the "Merger Agreement"), among Koninklijke DSM N.V., Merger Sub and Kensey Nash Corporation (the "Company"), in exchange for a cash payment equal to the product of (A) the excess of the $38.50 consideration payable in the merger for each share of the Company's common stock over the base price per share of such stock appreciation right, multiplied by (B) the number of shares of the Company's common stock subject to such stock appreciation right.
  • [F2]This option was cancelled pursuant to the merger contemplated by the Merger Agreement in exchange for a cash payment equal to the product of (A) the excess of the $38.50 consideration payable in the merger for each share of the Company's common stock over the exercise price per share of the option, multiplied by (B) the number of shares of the Company's common stock subject to such option.

Issuer

KENSEY NASH CORP

CIK 0001002811

Entity typeother

Related Parties

1
  • filerCIK 0001441287

Filing Metadata

Form type
4
Filed
Jun 25, 8:00 PM ET
Accepted
Jun 26, 6:52 PM ET
Size
16.1 KB